Positive results for BioChaperone® Lispro insulin in Phase 3

Adocia and Tonghua Dongbao announced positive results from the Phase 3 clinical trial of ultra-rapid insulin BioChaperone® Lispro in adults with type 1 diabetes in China. This study demonstrated the product's non-inferiority to Humalog® in terms of HbA1c reduction over 26 weeks and significant postprandial improvement.

The study, conducted by Tonghua Dongbao and approved by Chinese authorities, also confirmed the product's safety. The majority of side effects were mild or moderate and similar to those observed with Humalog®.

With these results, Adocia strengthens its position in the development of innovative treatments for diabetes. The collaboration between Adocia and Tonghua Dongbao could lead to an expansion of its offering in Asian markets, subject to regulatory approval.